Saturday 17 October 2026 Export SDGR’s income statement to Excel — free account

Schrodinger, Inc.

SDGR Healthcare Health Information Services

Schrodinger, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $255.9 million, up 23.3% from fiscal 2024. In the quarter to June 2026, revenue grew 7.54%, EPS grew 113.6% and free cash flow grew 34.4%, each against the same quarter a year earlier.

22.60 2.88 −11.30%

Follow SDGR

Alert me

Market cap: $1.9B
P/E: 0.0×
Fwd P/E: −7.1×
Dividend yield: —
F-score: 5/9
Altman Z: 1.10
Beneish M: −3.47
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.21

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	4	7	2	—	—	1	—	1	—

Insider Ownership 15.28%

Capital & Financial Ratios $m

Market Cap 1,910.00

Revenue 259.04

Net Income (54.33)

Free Cash Flow (130.27)

Net Debt (418.80)

Current Ratio 2.71

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (7.09)

P/S ratio 6.52

P/B ratio 5.13

Past 5Y EPS Growth —

This Y EPS Growth (16.60%)

Next Y EPS Growth 12.00%

Next Y revenue growth (5.62%)

Next 5Y EPS Growth 13.73%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 20.50%

10-year low 10-year high

P/B against its own 10 years 71.69%

10-year low 10-year high

EV/Sales against its own 10 years 24.96%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	469	367	402	419
Receivables	89	255	104	41
Inventory	—	—	—	—
Other	—	—	—	—
	568	635	519	470

	2023	2024	2025	Q'26
Payables	17	11	11	10
ST’ Debt	—	—	—	—
Other	—	—	—	—
	134	192	189	174

Compound Annual Growth %

	10y	5y	3y
Sales	—	18.81%	12.24%
Cash Flow	—	(3.67%)	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(10.22%)	(6.68%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	59	59	—	—	—
’25	60	55	54	87	256
’24	37	47	35	88	208
’23	65	35	43	74	217
’22	49	38	37	57	181
’21	32	30	30	46	138
’20	26	23	26	33	108

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(34)	—	—	—
’25	144	(52)	(62)	(16)	14
’24	(39)	(54)	(33)	(31)	(157)
’23	(31)	(18)	(50)	(37)	(137)
’22	(40)	(25)	(30)	(25)	(120)
’21	(11)	(29)	(11)	(20)	(71)
’20	(6)	(9)	(12)	44	17

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(17)	(34)	—	—	—
’25	143	(53)	(62)	(16)	12
’24	(43)	(55)	(35)	(32)	(165)
’23	(35)	(21)	(55)	(40)	(150)
’22	(41)	(27)	(33)	(26)	(128)
’21	(11)	(32)	(13)	(21)	(78)
’20	(7)	(10)	(12)	43	14

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.81)	0.08	—	—	—
’25	(0.82)	(0.59)	(0.45)	0.44	(1.41)
’24	(0.76)	(0.74)	(0.52)	(0.55)	(2.57)
’23	1.75	0.06	(0.86)	(0.32)	0.54
’22	(0.48)	(0.67)	(0.56)	(0.39)	(2.10)
’21	0.00	(0.49)	(0.49)	(0.43)	(1.42)
’20	(0.34)	(0.05)	0.05	(0.18)	(0.41)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	25.50	32.70	15.85	17.37	16.67	15.99	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	99.50	117.00	37.25	59.24	36.13	28.47
People
People	Employees	—	—	394	394	452	664	787	867	891	850
	Revenue/emp, $m	—	0.00	0.17	0.22	0.24	0.21	0.23	0.25	0.23	0.30
Income, $m
Income, $m	Revenue	—	56	67	86	108	138	181	217	208	256
	Gross margin, %	—	71.39	64.43	57.39	58.72	47.57	55.83	64.93	63.64	55.74
	EBT	—	(17)	(28)	(26)	(26)	(101)	(149)	43	(186)	(102)
	EBT margin, %	—	(30.63)	(42.54)	(30.36)	(24.32)	(73.09)	(82.41)	19.81	(89.48)	(39.99)
	Net income	—	0	(28)	(26)	(27)	(101)	(149)	41	(187)	(103)
	Depreciation	—	2	3	4	4	3	4	6	6	6
Per share, $
Per share, $	Revenue	—	0.88	11.55	14.25	1.80	1.95	2.54	3.02	2.86	3.48
	Earnings	—	(0.27)	(4.93)	(4.01)	(0.41)	(1.42)	(2.10)	0.57	(2.57)	(1.41)
	Cash flow	—	(0.24)	(4.11)	(4.34)	0.28	(1.00)	(1.68)	(1.90)	(2.17)	0.19
	Capex	—	0.00	(0.91)	(0.31)	(0.04)	(0.10)	(0.11)	(0.19)	(0.10)	(0.02)
	Free cash flow	—	(0.24)	(5.02)	(4.65)	0.24	(1.10)	(1.79)	(2.09)	(2.27)	0.17
	Book value	—	0.58	15.62	16.36	10.40	7.89	6.29	7.64	5.80	4.96
	Shares, m	—	63	6	6	60	71	71	72	73	73
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	61.31	0.00	0.00
	P/S	—	2.01	2.01	2.01	43.97	17.83	7.20	11.64	6.75	5.13
	P/B	—	0.00	0.00	0.00	7.62	4.41	2.91	4.60	3.33	3.61
	EV/Sales	—	1.00	1.00	1.00	38.02	13.63	4.68	9.47	4.98	3.56
	EV/FCF	—	(3.07)	(3.07)	(3.07)	289.02	(24.14)	(6.63)	(13.67)	(6.28)	73.12
Cash, $m
Cash, $m	Operating cash flow	—	(15)	(24)	(26)	17	(71)	(120)	(137)	(157)	14
	Capex	—	(4)	(5)	(2)	(3)	(7)	(8)	(13)	(7)	(1)
	Free cash flow	—	(15)	(29)	(28)	14	(78)	(128)	(150)	(165)	12
Balance, $m
Balance, $m	Working capital	—	30	78	74	610	534	425	434	443	330
	Total debt	—	—	—	206	12	80	116	—	—	—
	Net debt	—	(36)	(84)	(86)	(643)	(579)	(456)	(469)	(367)	(402)
	Shareholders’ equity	—	37	90	98	624	557	448	549	421	364
Returns, %
Returns, %	ROA	—	(19.46)	(47.09)	(17.81)	(5.43)	(13.36)	(20.65)	5.46	(23.01)	(13.33)
	ROIC	—	0.00	(288.46)	(202.87)	0.00	0.00	0.00	(138.97)	(242.29)	0.00
	ROE	—	29.75	48.62	29.80	(9.22)	(17.00)	(29.69)	8.17	(38.58)	(26.29)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HTFL Heartflow, Inc.	$4.4B	— (loss-making)	— (loss-making)	+47.57% (above 0%: growing)	n/m	+62.62% (above 0%: growing)	83.00%	(27.93%)	Compare
PRVA Privia Health Group, Inc.	$2.9B	102×	87.8×	+21.39% (above 0%: growing)	+250.00% (above 0%: growing)	−86.20% (below 0%: shrinking)	9.93%	1.86%	Compare
SDGR Schrodinger, Inc.	$1.9B	— (loss-making)	— (loss-making)	+7.54% (above 0%: growing)	n/m	+34.43% (above 0%: growing)	55.07%	(70.55%)
OMCL Omnicell, Inc.	$1.6B	41.6×	55.1×	+7.45% (above 0%: growing)	+341.67% (above 0%: growing)	+107.90% (above 0%: growing)	48.98%	10.39%	Compare
CERT Certara, Inc.	$1.5B	— (loss-making)	— (loss-making)	+0.99% (above 0%: growing)	n/m	−78.46% (below 0%: shrinking)	62.34%	(0.21%)	Compare
GDRX GoodRx Holdings, Inc.	$1.2B	62.7×	30.9×	−1.31% (below 0%: shrinking)	−25.00% (below 0%: shrinking)	+112.45% (above 0%: growing)	89.52%	11.79%	Compare
OMDA Omada Health, Inc.	$1.1B	252×	143×	+43.12% (above 0%: growing)	n/m	+45.71% (above 0%: growing)	72.62%	4.04%	Compare
TDOC Teladoc Health, Inc.	$1.1B	— (loss-making)	— (loss-making)	−3.95% (below 0%: shrinking)	n/m	−27.07% (below 0%: shrinking)	68.56%	(6.11%)	Compare
HSTM HealthStream, Inc.	$1.0B	46.0×	34.4×	+12.55% (above 0%: growing)	+27.78% (above 0%: growing)	+362.71% (above 0%: growing)	65.35%	9.94%	Compare
Median of peers	$1.3B	62.7×	55.1×	+10.00%	+138.89%	+54.17%	66.96%	2.95%

All 51 Health Information Services stocks →

Schrodinger, Inc. (SDGR) key facts

Strength: Schrodinger, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $255.9 million, up 23.3% from fiscal 2024.
Schrodinger, Inc. (SDGR) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SDGR traded at $22.60, a market capitalization of $1.9 billion.
Return on equity was −26.3% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.10 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.